OBJECTIVES: The objective of this study is to evaluate the cost-effectiveness of aflibercept compared to ranibizumab for the treatment of wet age-related macular degeneration (wAMD) in Turkey. METHODS: A Markov model consisting of six health states on vision impairment as “no vision impairment; mild vision impairment; moderate vision impairment; severe vision impairment; total blindness; death” with a 20-year timeframe was adapted to the Turkish setting through an expert panel. Clinical transition inputs between visual acuity states and safety data were mainly derived from the results of Phase III VIEW-1 and VIEW-2 trials. Economic inputs were based on the expert opinion addressing local treatment, monitoring and adverse event management algorithms. The primary and secondary endpoints for the study were blind years and QALYs, respectively.  Analyses were conducted from the Turkish Payer Social Security Institution perspective. All costs were calculated in Turkish Liras (TL) and then converted to USD using TL/USD currency rate as 2,1 (mid-2014). RESULTS: Aflibercept was associated with 6,614 blind years and 4,805 QALYs, while ranibizumab was associated with 6,599 blind years and 4,810 QALYs; resulting in total of 0,015 more blind years and 0,005 less QALYs for aflibercept compared with ranibizumab in the treatment of wAMD. Total costs associated with aflibercept and ranibizumab were 25.954 USD and 30.311 USD respectively; resulting with a total of 4.357 USD less costs for aflibercept compared with ranibizumab, driven by savings in medication, administration and monitoring costs. CONCLUSIONS: Aflibercept was found as the cost-effective treatment option when compared with ranibizumab in the treatment of wAMD  in Turkish setting. Aflibercept was associated with significant less cost leading to savings in medication, administration and monitoring costs; while being clinically equivalent with negligible benefits as blind years averted and QALYs gained in comparison with ranibizumab.